In total, 46.3% (321/693) of all NSCLC in early stage tumors (IA 93/236; IB 38/84, IIA 15/35, IIB 62/128, IIIA 113/210) and 53.0% (422/796) in advanced-stage tumors (IIIB 78/ 127, IIIC 21/37, IV 324/632) presented a positive expression of PD-L1 (TPS ≥1). Here, CD274 is linked to non-small cell lung carcinoma.